CHEMIOTERAPIA METRONOMICA NEL PAZIENTE ONCOLOGICO ANZIANO
S. Bordonaro, S. Rametta Giuliano, H. Lipari, S. Clementi, P. Tralongo
Vol.1 (2016), issue 2, pag. 43-57

Received 22/02/2016
Accepted for pubblication 29/05/2016
Published May 2016
Review by Single-blind
jQuery UI Dialog - Animation

Systemic chemotherapy represents the most commonly used therapeu- tic strategy for patients with advanced cancer. Cytotoxic drugs cause cell death by inducing DNA damage and cell replication inhibition. The ma- jority of antiblastic drugs display their effects on both neoplastic and healthy cellular lines. Therefore, the lack of a target action is the cause of several toxicities related to their administration. Nevertheless, recent advances in earlier diagnosis and the use of more effective chemotherapy regimens have improved patients’ survival. Indeed, cancer may be considered a chronic disease and different treatments lines are usually administered to each patient more and more often for a long time. The reason why there is a needs of effective and well tolerated drugs. In this regard, metronomic chemotherapy (mCT), which is characterized by low dose oral continuous drug administration, has been shown to be effective with acceptable toxicity in different solid toumors and may rep- resent an alternative treatment approach expecially in elderly patients. This review report the rationale and the possible applications of mCT in the elderly patients.